apraglutide
Peptideexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04699032)
Timeline
Indications
Mechanism of action
GLP2R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06002555 | Phase 1 | May 23, 2023 | VectivBio AG |
| NCT05995704 | Phase 1 | Mar 2, 2023 | VectivBio AG |
| NCT05706623 | Phase 1 | Jan 30, 2023 | VectivBio AG |
| NCT05415410 | Phase 2 | May 25, 2022 | VectivBio AG |
| NCT05018286 | Phase 3 | Jul 13, 2021 | VectivBio AG |
| NCT04964986 | Phase 2 | Jun 14, 2021 | VectivBio AG |
| NCT04627025 | Phase 3 | Jan 26, 2021 | VectivBio AG |
| NCT04699032 | Phase 1 | Nov 30, 2020 | VectivBio AG |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VectivBio AG | For profit | 8 | 8 | 3 | 2020 |
1 organizations
Page 1 / 1